Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature

Background: In the last 10 years, the management of patients with gastric cancer liver metastases (GCLM) has changed from chemotherapy alone, towards a multidisciplinary treatment with liver surgery playing a leading role. The aim of this systematic review and meta-analysis is to assess the efficacy of hepatectomy for GCLM and to analyze the impact of related prognostic factors on long-term outcomes. Methods: The databases PubMed (Medline), EMBASE, and Google Scholar were searched for relevant articles from January 2010 to September 2020. We included prospective and retrospective studies that reported the outcomes after hepatectomy for GCLM. A systematic review of the literature and meta-analysis of prognostic factors was performed. Results: We included 40 studies, including 1573 participants who underwent hepatic resection for GCLM. Post-operative morbidity and 30-day mortality rates were 24.7% and 1.6%, respectively. One-year, 3-years, and 5-years overall survival (OS) were 72%, 37%, and 26%, respectively. The 1-year, 3-years, and 5-years disease-free survival (DFS) were 44%, 24%, and 22%, respectively. Well-moderately differentiated tumors, pT1–2 and pN0–1 adenocarcinoma, R0 resection, the presence of solitary metastasis, unilobar metastases, metachronous metastasis, and chemotherapy were all strongly positively associated to better OS and DFS. Conclusion: In the present study, we demonstrated that hepatectomy for GCLM is feasible and provides benefits in terms of long-term survival. Identification of patient subgroups that could benefit from surgical treatment is mandatory in a multidisciplinary setting.

Download Full-text

A Retrospective Analysis of Cancer of Unknown Primary in Ibaraki Prefectural Central Hospital

Annals of Oncology ◽

10.1093/annonc/mdt459.34 ◽

2013 ◽

Vol 24 ◽

pp. ix38

Author(s):

F. Fujisawa ◽

S. Meshihtsuka ◽

S. Mitsuhashi ◽

M. Hori ◽

T. Kaburagi ◽

...

Keyword(s):

Retrospective Analysis ◽

Cancer Of Unknown Primary ◽

Unknown Primary ◽

Central Hospital ◽

Prefectural Central Hospital

Download Full-text

Retrospective Analysis of the Prognostic Factors That Influence Treatment Response and Survival of Patients with Cancer of Unknown Primary

QJM ◽

10.1093/qjmed/hcab103.008 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Zeinab Abdlelhafeez ◽

Dina Ragab ◽

Nervana Hussien ◽

Fatma El – Tabakh

Keyword(s):

Prognostic Factors ◽

Treatment Response ◽

Retrospective Analysis ◽

Clinical Oncology ◽

Cancer Registries ◽

Cancer Of Unknown Primary ◽

Response To Treatment ◽

Unknown Primary ◽

University Hospitals ◽

Patients With Cancer

Abstract Background Cancers of unknown primary site (CUPs) are heterogeneous group of metastatic tumors for which a standardized diagnostic work-up could not recognize the site of origin at the time of diagnosis. Cancer registries around the world report the incidence of CUP in the range of 3%–5% of all malignancies, worldwide the overall age-standardized incidence per 100.000 people per year is 4–19 cases. CUP therefore ranks among the top 10 commonest malignancies. CUP occurs equally in both males and females, at average age 60 years old. Incidence of CUP in Egypt is 6.1%in males and 5.5% in females. Aim of the Work to retrospectively identify the prognostic factors that influence treatment outcome and survival of patients diagnosed with cancer of unknown primary treated patients at Clinical Oncology departments at Ain Shams University Hospitals (ASUH) and Helwan University Hospitals by retrospective analysis. Patients and Methods At the department of clinical oncology, Ain Shams University, 102 patients with cancer of unknown primary were identified in the period between January 2012 and December 2017, all patients data was collected and reviewed. The primary end point of this study is to identify different prognostic factors that influence treatment response and OS in 102 patients with CUP in the period from January 2012 to December 2017. Results Patients with PS 1, with no comorbidities showed better treatment response, also Patients younger than 65year, presented with PS1, with no comorbidity had longer survival. Conclusion CUP has a poor prognosis. Some prognostic factors that affect response to treatment and survival in these patients, which may be identified.

Download Full-text